CD274 and non-small cell lung carcinoma: CD45RO+ TILs的密度与患者年龄、吸烟、肿瘤分期和病理类型显著相关。在NSCLC和肺腺癌(lung adenocarcinoma, LUAD)患者中,基质区高密度CD45RO+ TILs具有更长的总生存期(overall survival, OS)(NSCLC: P=0.007; LUAD: P < 0.001),并且是OS的独立预后因素(NSCLC: HR=0.559, 95%CI: 0.377-0.829, P=0.004; LUAD: HR=0.352, 95%CI: 0.193-0.641, P=0.001)。联合肿瘤细胞的PD-L1评分以及所有区域CD45RO+ TILs的浸润评分将患者分为四组:其中PD-L1+/CD45RO+患者无病生存期(disease-free survival, DFS)最长,PD-L1+/CD45RO-的患者DFS时间最短,并可作为DFS预后的独立因素(HR=2.221, 95%CI: 1.258-3.919, P=0.006)。